[go: up one dir, main page]

HUE039750T2 - Hidroxi-buspiron mozgászavarok kezelésére - Google Patents

Hidroxi-buspiron mozgászavarok kezelésére

Info

Publication number
HUE039750T2
HUE039750T2 HUE15744478A HUE15744478A HUE039750T2 HU E039750 T2 HUE039750 T2 HU E039750T2 HU E15744478 A HUE15744478 A HU E15744478A HU E15744478 A HUE15744478 A HU E15744478A HU E039750 T2 HUE039750 T2 HU E039750T2
Authority
HU
Hungary
Prior art keywords
hydroxybuspirone
treatment
movement disorders
disorders
movement
Prior art date
Application number
HUE15744478A
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael S Thomsen
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Publication of HUE039750T2 publication Critical patent/HUE039750T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE15744478A 2014-06-26 2015-06-25 Hidroxi-buspiron mozgászavarok kezelésére HUE039750T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201470388 2014-06-26
DKPA201470389 2014-06-26
DKPA201570102 2015-02-26
DKPA201570101 2015-02-26

Publications (1)

Publication Number Publication Date
HUE039750T2 true HUE039750T2 (hu) 2019-02-28

Family

ID=53761914

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15744478A HUE039750T2 (hu) 2014-06-26 2015-06-25 Hidroxi-buspiron mozgászavarok kezelésére

Country Status (13)

Country Link
US (1) US11478476B2 (hu)
EP (1) EP3160464B1 (hu)
JP (1) JP6634445B2 (hu)
KR (2) KR20170021848A (hu)
CN (1) CN107635555B (hu)
AU (1) AU2015281448B2 (hu)
CA (1) CA2950469C (hu)
DK (1) DK3160464T3 (hu)
ES (1) ES2686529T3 (hu)
HU (1) HUE039750T2 (hu)
PL (1) PL3160464T3 (hu)
PT (1) PT3160464T (hu)
WO (1) WO2015197079A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067688A1 (en) * 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
EP3661500A1 (en) * 2017-07-31 2020-06-10 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
MX2022009528A (es) * 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
JP7620694B2 (ja) 2020-07-17 2025-01-23 ノバルティス アーゲー オピオイド使用の低減用医薬品及びオピオイド禁断の促進用医薬品
JP2024521959A (ja) * 2021-06-09 2024-06-04 プロニラス コーポレイション オピエート離脱又はオピエート再発に関連する状態を治療又は予防する方法
CN113341026A (zh) * 2021-07-02 2021-09-03 北京和合医学诊断技术股份有限公司 Lc_ms_ms检测丁螺环酮及其代谢产物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
WO1993013766A1 (en) * 1992-01-07 1993-07-22 Merrell Dow Pharmaceuticals Inc. Treatment of involuntary movements with 5ht1a receptor agonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
EP1047436B1 (en) * 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinates for use in treating hyperkinesias
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
US20050137206A1 (en) 1999-08-05 2005-06-23 Yevich Joseph P. Method for treatment of anxiety and depression
US6593331B2 (en) 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain
US6686361B2 (en) * 2001-07-24 2004-02-03 Bristol-Myers Squibb Company R-6-hydroxy-buspirone
US6821976B2 (en) * 2001-07-24 2004-11-23 Bristol-Myers Squibb Company S-6-hydroxy-buspirone
PL2298766T3 (pl) 2005-03-03 2014-09-30 H Lundbeck As Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20110183995A1 (en) 2008-06-24 2011-07-28 Neurosearch A/S Eltoprazine for suppression of l-dopa induced dyskinesias
WO2011026890A1 (en) 2009-09-07 2011-03-10 Neurosearch A/S 2, 3, 6 -triamino substituted pyridines as kv7 (kcnq) channel modulators
KR101825972B1 (ko) * 2010-10-15 2018-02-06 콘테라 파르마 에이피에스 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합
MY169068A (en) 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders

Also Published As

Publication number Publication date
PT3160464T (pt) 2018-10-12
CN107635555B (zh) 2021-02-26
EP3160464A1 (en) 2017-05-03
KR20170021848A (ko) 2017-02-28
EP3160464B1 (en) 2018-07-18
KR102527805B1 (ko) 2023-04-28
AU2015281448B2 (en) 2020-04-09
US11478476B2 (en) 2022-10-25
CA2950469A1 (en) 2015-12-30
US20170128446A1 (en) 2017-05-11
JP2017519827A (ja) 2017-07-20
ES2686529T3 (es) 2018-10-18
JP6634445B2 (ja) 2020-01-22
CA2950469C (en) 2022-09-20
DK3160464T3 (en) 2018-10-29
KR20230042131A (ko) 2023-03-27
CN107635555A (zh) 2018-01-26
AU2015281448A1 (en) 2017-01-05
WO2015197079A1 (en) 2015-12-30
PL3160464T3 (pl) 2018-12-31

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
IL251529A0 (en) Use of cannabinoids in the treatment of epilepsy
IL247841A0 (en) Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
HK1232147A1 (zh) 用於治療纖維化的賽尼克韋羅
GB201403093D0 (en) Therapeutic compounds and their use
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL247589A0 (en) Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
IL251904A0 (en) Epilimod for use in the treatment of melanoma
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL246855A0 (en) Materials for use in the treatment of retinitis
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
EP3200795A4 (en) Use of agents for treating fat-related disorders
IL252043B (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders
ZA201408464B (en) Composition for the use in treatment of asthma
GB201415302D0 (en) New therapeutic use
GB201417719D0 (en) New treatment
GB201410387D0 (en) Compounds and their therapeutic use
GB201408384D0 (en) New treatment
GB201403496D0 (en) Compounds and their therapeutic use